Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs.

view more →

Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research.

view more →

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2.

view more →

Their clinical research software accelerates timelines by automating multiple high impact processes.

view more →

Boomerang Medical is developing a technology to advance the treatment of autoimmune diseases by using electrical nerve stimulation

view more →

Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI

view more →

Code Bio is a preclinical stage company developing novel genetic medicines.

view more →

Endogenex is a clinical stage company, founded to improve outcomes for people living with Type 2 Diabetes.

view more →

Gozio promotes loyalty and growth for a health system by creating a system-specific app that enhances the patient experience.

view more →

Huma.ai is a next-generation low code/no code data science solution for the life sciences industry.

view more →

IMMvention is developing novel, first-in-class therapies for treating hemolytic anemias.

view more →

iVEAcare is developing innovative neuromodulation therapy to treat unmet clinical needs impacting large patient populations.

view more →

We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles.

view more →

Synaptrix is focused on developing and commercializing drug-free, long-lasting solutions for post-operative pain management.

view more →

Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910